Qualify for free participation
$85 per visit plus free transportation
Do you suffer from migraine?
If so, you may qualify for our migraine study to help us learn about an investigational medication being tested for the prevention of migraine.
Chronic Migraine Prevention Study
Biohaven Pharmaceuticals is studying how well oral zavegepant works compared to a placebo (like a sugar pill) to prevent migraines from occurring in people who have chronic migraine. If you are at least 18 years of age and suffer from chronic migraine, you may qualify.
Find out if you qualify for a clinical research study. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
*You do not need insurance to participate.
This is a research study, or clinical trial, to test a new investigational medication. An investigational medication is one that is not approved by the US FDA. The purpose of the research study is to test how well zavegepant works compared to a placebo (like a sugar pill) as a preventative treatment in people with chronic migraine.
About 2,900 study participants could be screened and about 1,440 study participants could enter into the double blind treatment phase. Double blind means that neither you, your doctor, or the study sponsor Biohaven, will know if you are taking zavegepant or placebo (like sugar pill).
This study will test how well zavegepant works compared to a placebo (like a sugar pill) to prevent migraines from occurring in peopl with chronic migraine. This will be measured by counting the number of migraine days you have each month.
If you qualify, your participation in this study will last approximately 24 weeks (1 month taking your usual migraine medications, 3 months taking zavagepant or placebo and 2 months follow up, when you are no taking zavegepant or placebo). You will have 9 study visits to the study center. Some of the participants in this study will take 100 mg zavegepant daily, some will take 200 mg zavegepany daily, and some subjects will take placebo (like a sugar pill).
For more detailed information visit clinicaltrials.gov
Before a medication can be approved for treatment, the FDA requires that it be tested in a clinical study to evaluate the safety and efficacy of the drug.
Clinical trials take place in medical centers around the world, and involve volunteers helping doctors look at new ways to treat conditions.
Clinical trials represent the latest research about your condition, and can offer new treatment options.
Migraine is a chronic and debilitating disorder that affects approximately 15% of the population.
Migraines are characterized by recurrent attacks lasting 4 to 72 hours with multiple symptoms, including pulsating (throbbing) headaches of moderate to severe pain that could be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).
Migraine is a chronic and debilitating disorder that affects approximately 15% of the population.
Migraines are characterized by recurrent attacks lasting 4 to 72 hours with multiple symptoms, including pulsating (throbbing) headaches of moderate to severe pain that could be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).
Clinical studies (also called clinical trials) are used to learn about the safety and effectiveness of possible new medications, medical devices, and medical procedures. Although there are many types of clinical trials, all United States-based clinical trials must conform to strict rules set by the U.S. Food and Drug Administration (FDA). These rules help protect the rights and safety of those who volunteer to take part in clinical trials.
The study is being conducted on behalf of Biohaven Pharmaceuticals by multiple sites (research clinics or hospitals) across the United States with trained and qualified medical specialists.
No. If you qualify and are chosen to participate, you will receive all study-related care, including investigational study drug, at no cost to you.
About 1750 people will be screened and about 1400 people will enter into the treatment phase in this study.
Your participation in this study will last approximately 11 weeks and will include approximately 3 study visits to the study center.
Like all clinical studies, your participation is fully voluntary. You may leave the study at any time.